Delivery Order SPE2DB24D2011-SPE2DB25FBRHW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,769.15 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract issued on August 5, 2025, with performance at the vendor's Conshohocken, Pennsylvania headquarters. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with established heart...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, valued at $1,041.42. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,232.28 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 13, 2025. This competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The award carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,614.91 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed price contract was competitively awarded on July 28, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency has awarded a delivery order valued at $9,104.70 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The primary contractor,...
- The Defense Logistics Agency awarded a $1,041.42 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 30, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with a ceiling value of $1,041.42. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to treat high cholesterol and reduce...
- The Defense Logistics Agency awarded a delivery order valued at $1,964.30 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location in the same city. REPATHA is a prescription...
- The Defense Logistics Agency awarded a delivery order valued at $6,293.41 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injector pharmaceutical product. The contract, executed on August 7, 2025, with completion targeted for August 8, 2025, utilized firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $12,889.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award to the pharmaceutical distributor and represents a continuation of the company's ongoing supply relationship with DLA. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRHWDelivery Order
The Defense Logistics Agency awarded a $20,623.85 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in eligible patient populations. This delivery order supports the Defense Health Agency's medical supply requirements, leveraging AmerisourceBergen's established role as a critical pharmaceutical vendor for military and veteran healthcare systems. The award reflects the company's continued capability to fulfill federal procurement requirements for specialty medications and injectable pharmaceutical products across the military healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.6k | 7/21/25 |